Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000

Next Previous
X
Search
Trial Profile

Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sulcardine (Primary) ; Paroxetine
  • Indications Atrial fibrillation
  • Focus Pharmacokinetics
  • Sponsors HUYA Bioscience International

    • Most Recent Events

    • 02 Sep 2024 Results assessing pharmacokinetics, safety and drug-drug interaction of a single sulcardine intravenous infusion in healthy subjects presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
    • 17 May 2022 Status changed from recruiting to completed according to a HUYABIO International media release.
    • 14 Jun 2021 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top